Zacks Investment ResearchMon, 29 Jun 2026 14:01:15 GMTNovo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on ItNVO-0.28%
Zacks Investment ResearchTue, 23 Jun 2026 16:11:07 GMTNVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research PushNVO-0.28%
Seeking AlphaTue, 23 Jun 2026 12:54:16 GMTNovo Nordisk: The Selloff Looks Like A Gift, And I'm BuyingNVO-0.28%
The Motley FoolSat, 20 Jun 2026 16:15:00 GMTNovo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?NVO-0.28%
Zacks Investment ResearchThu, 18 Jun 2026 15:06:14 GMTCan Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?NVO-0.28%
Zacks Investment ResearchTue, 16 Jun 2026 14:01:13 GMTNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowNVO-0.28%
Seeking AlphaTue, 16 Jun 2026 13:10:00 GMTNovo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)NVO-0.28%
Zacks Investment ResearchMon, 15 Jun 2026 15:41:05 GMTNovo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?NVO-0.28%
Zacks Investment ResearchFri, 12 Jun 2026 14:11:04 GMTNovo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security BreachNVO-0.28%
Zacks Investment ResearchThu, 11 Jun 2026 22:46:14 GMTNovo Nordisk (NVO) Outpaces Stock Market Gains: What You Should KnowNVO-0.28%
BenzingaThu, 11 Jun 2026 17:34:46 GMTNovo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy TabletNVO-0.28%
CNBC TelevisionTue, 09 Jun 2026 18:42:38 GMTNovo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 beforeNVO-0.28%
CNBC TelevisionTue, 09 Jun 2026 18:40:25 GMTNovo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for WegovyNVO-0.28%
CNBC TelevisionTue, 09 Jun 2026 17:30:43 GMTNovo Nordisk CEO: We are a cardiometabolic powerhouseNVO-0.28%
Zacks Investment ResearchMon, 08 Jun 2026 14:41:33 GMTCan Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?NVO-0.28%
WSJMon, 08 Jun 2026 06:42:00 GMTNovo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since LaunchNVO-0.28%
